New knee shot aims to ease arthritis pain in early trial

NCT ID NCT07652372

ENROLLING_BY_INVITATION Symptom relief Sponsor: ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called RAB001, given as an injection into the knee joint, for people with knee osteoarthritis. The study includes 60 participants aged 40 to 75 who have persistent knee pain despite conservative treatments. Researchers are primarily checking safety and how the drug moves through the body, while also looking for signs of pain relief and improved function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAB001
What this could lead to: If it works, this could point toward a new injection to ease pain and improve knee function in people with osteoarthritis.
What could go wrong: This is a very early Phase 1 trial with only 60 people, focused on safety. It may not show clear benefit, and higher doses could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS

Contacts and locations

Locations

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijin, Beijin, 100730, China
The Third Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050051, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.